Ads by Google

Child Health and Safety

Vaccine Study To Help Prevent Most Common Viral Causes Of Childhood Respiratory Illness

MedImmune is dosing at-risk children six months to 24 months of age in a Phase 1 trial of a vaccine designed to help prevent respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV-3) infections.

Health and Wellness: